Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorElander, N O-
dc.contributor.authorAughton, K-
dc.contributor.authorGhaneh, P-
dc.contributor.authorNeoptolemos, J P-
dc.contributor.authorPalmer, D H-
dc.contributor.authorCox, T F-
dc.contributor.authorCampbell, F-
dc.contributor.authorCostello, E-
dc.contributor.authorHalloran, C M-
dc.contributor.authorMackey, J R-
dc.contributor.authorScarfe, A G-
dc.contributor.authorValle, J W-
dc.contributor.authorMcDonald, A C-
dc.contributor.authorCarter, R-
dc.contributor.authorTebbutt, Niall C-
dc.contributor.authorGoldstein, D-
dc.contributor.authorShannon, J-
dc.contributor.authorDervenis, C-
dc.contributor.authorGlimelius, B-
dc.contributor.authorDeakin, M-
dc.contributor.authorCharnley, R M-
dc.contributor.authorAnthoney, Alan-
dc.contributor.authorLerch, M M-
dc.contributor.authorMayerle, J-
dc.contributor.authorOláh, A-
dc.contributor.authorBüchler, M W-
dc.contributor.authorGreenhalf, W-
dc.identifier.citationBritish Journal of Cancer 2018; 118(7): 947-954-
dc.description.abstractDihydropyrimidine dehydrogenase (DPD) tumour expression may provide added value to human equilibrative nucleoside transporter-1 (hENT1) tumour expression in predicting survival following pyrimidine-based adjuvant chemotherapy. DPD and hENT1 immunohistochemistry and scoring was completed on tumour cores from 238 patients with pancreatic cancer in the ESPAC-3(v2) trial, randomised to either postoperative gemcitabine or 5-fluorouracil/folinic acid (5FU/FA). DPD tumour expression was associated with reduced overall survival (hazard ratio, HR = 1.73 [95% confidence interval, CI = 1.21-2.49], p = 0.003). This was significant in the 5FU/FA arm (HR = 2.07 [95% CI = 1.22-3.53], p = 0.007), but not in the gemcitabine arm (HR = 1.47 [0.91-3.37], p = 0.119). High hENT1 tumour expression was associated with increased survival in gemcitabine treated (HR = 0.56 [0.38-0.82], p = 0.003) but not in 5FU/FA treated patients (HR = 1.19 [0.80-1.78], p = 0.390). In patients with low hENT1 tumour expression, high DPD tumour expression was associated with a worse median [95% CI] survival in the 5FU/FA arm (9.7 [5.3-30.4] vs 29.2 [19.5-41.9] months, p = 0.002) but not in the gemcitabine arm (14.0 [9.1-15.7] vs. 18.0 [7.6-15.3] months, p = 1.000). The interaction of treatment arm and DPD expression was not significant (p = 0.303), but the interaction of treatment arm and hENT1 expression was (p = 0.009). DPD tumour expression was a negative prognostic biomarker. Together with tumour expression of hENT1, DPD tumour expression defined patient subgroups that might benefit from either postoperative 5FU/FA or gemcitabine.-
dc.titleExpression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.-
dc.typeJournal Article-
dc.identifier.journaltitleBritish Journal of Cancer-
dc.identifier.affiliationFrom the Cancer Research U.K. Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, UK-
dc.identifier.affiliationCross Cancer Institute and University of Alberta, Alberta, Canada-
dc.identifier.affiliationUniversity of Manchester/The Christie NHS Foundation Trust, Manchester, UK-
dc.identifier.affiliationThe Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK-
dc.identifier.affiliationGlasgow Royal Infirmary, Glasgow, Scotland, UK-
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationPrince of Wales hospital and Clinical School University of New South Wales, New South Wales, Australia-
dc.identifier.affiliationNepean Cancer Centre and University of Sydney, Sydney, Australia-
dc.identifier.affiliationThe Agia Olga Hospital, Athens, Greece-
dc.identifier.affiliationDepartment of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden-
dc.identifier.affiliationUniversity Hospital, North Staffordshire, UK-
dc.identifier.affiliationFreeman Hospital, Newcastle upon Tyne, UK-
dc.identifier.affiliationSt James's University Hospital, Leeds, UK-
dc.identifier.affiliationDepartment of Medicine A, University Medicine Greifswald, Greifswald, Germany-
dc.identifier.affiliationDepartment of Medicine II, University Hospital of the Ludwig-Maximilians-University, Munich, Germany-
dc.identifier.affiliationThe Petz Aladar Hospital, Gyor, Hungar-
dc.identifier.affiliationThe Department of Surgery, University of Heidelberg, Heidelberg, Germany-
dc.type.austinJournal Article-, Niall C
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en- Oncology- Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 21, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.